Bioskin GmbH

Since its inception in 1992 by Dr. Johannes Gassmueller, bioskin® has been recognized as a valuable partner for dermatological product development.  Starting as a small Contract Research Organisation specialized in conducting early phase safety and efficacy trials in our clinical unit in Hamburg, bioskin® has grown into a full service CRO offering all core services for management of Phase I-IV drug trials and claim support / safety studies. 

Headquartered in Hamburg, Germany, bioskin® added a second clinical unit in Germany’s capital and largest city, Berlin, in 2002 to expand recruitment capabilities for both patients with dermatological conditions and healthy volunteers. Further, bioskin® has established a network of dermatologists and university hospitals  and has access to investigators across Europe and other parts of the world for the conduct of multinational studies in all dermatological indications. Later phase multicenter, multinational trials are managed by our project teams based in Hamburg.

In 2004 bioskin® was acquired by Dow Pharmaceutical Sciences, Inc. , the leading contract developer of topical products in the United States. While bioskin® operations have remained completely independent from Dow, if desired by the client it is possible for us to work closely with Dow and leverage their expertise and services for formulation and topical product development through licensing.

Our global capabilities were further boosted in 2009 by the formation of The International Dermatology Alliance in Clinical Research in cooperation with Cu-Tech, LLC, a leading US dermatology-only CRO, extending our reach into North America.

Burchardstrasse 17 20095 Hamburg, Germany